Essential package of palliative care for women with cervical cancer: Responding to the suffering of a highly vulnerable population

Eric L. Krakauer
Khadidjatou Kane
Xiaoxiao Kwete
Gauhar Afshan
Lisa Bazzett-Matabele

See next page for additional authors

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_anaeesth

Part of the Anesthesiology Commons, and the Oncology Commons
Authors
Essential Package of Palliative Care for Women With Cervical Cancer: Responding to the Suffering of a Highly Vulnerable Population

Eric L. Krakauer, MD, PhD1,2,3; Khadidjatou Kane, MD1,4; Xiaoxiao Kwete, MD, MPH5; Gauhar Afshan, MBBS6; Lisa Bazzett-Matabele, MD7,8; Danta Dona Ruthvie Bien-Aïmé, RN, MS9,10,11; Lawrence F. Borges, MD12; Sarah Byrne-Martelli, DMin1; Stephen Connor, PhD13; Raimundo Correa, MD14; C. R. Beena Devi, MD15; Mamadou Diop, MD16; Shekinah N. Elmore, MD, MPH17; Nahla Gafer, MD18,19; Annekathryn Goodman, MD20,21; Surbhi Grover, MD22,23; Annette Hasenburg, MD24; Kelly Irwin, MD25; Mihir Kamdar, MD26; Suresh Kumar, MD27; Quynh Xuan Nguyen Truong, MPH28,29,30; Tom Randall, MD30,31; Maryam Rassoul, PhD31; Cristiana Sessa, MD32; Dingle Spence, MBBS33,34; Ted Trimble, MD35; Cherian Varghese, MD, PhD36; and Elena Fidarova, MD37

Women with cervical cancer, especially those with advanced disease, appear to experience suffering that is more prevalent, complex, and severe than that caused by other cancers and serious illnesses, and approximately 85% live in low- and middle-income countries where palliative care is rarely accessible. To respond to the highly prevalent and extreme suffering in this vulnerable population, we convened a group of experienced experts in all aspects of care for women with cervical cancer, and from countries of all income levels, to create an essential package of palliative care for cervical cancer (EPPCCC). The EPPCCC consists of a set of interventions, medicines, simple equipment, social supports, and human resources, and is designed to be safe and effective for preventing and relieving all types of suffering associated with cervical cancer. It includes only inexpensive and readily available medicines and equipment, and its use requires only basic training. Thus, the EPPCCC can and should be made accessible everywhere, including for the rural poor. We provide guidance for integrating the EPPCCC into gynecologic and oncologic care at all levels of health care systems, and into primary care, in countries of all income levels.

JCO Global Oncol 7:873-885. © 2021 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

INTRODUCTION

Cervical cancer, a preventable disease, is the fourth most common cancer in women globally and disproportionately affects the poor. The International Agency for Research on Cancer estimates that, in 2018, 570,000 women were diagnosed with cervical cancer and 311,000 women died of it. More than 85% of cases occurred in low- or middle-income countries (LMICs) or among economically disadvantaged communities in high-income countries, and it was the most common cause of cancer-related death in sub-Saharan Africa.1 We described the geographic distribution of cervical cancer and of cervical cancer mortality in more detail elsewhere.2

The WHO Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem, adopted by the 73rd World Health Assembly in August 2020, outlines a comprehensive roadmap toward elimination within the current century that entails achievement of the 90-70-90 targets associated with three main pillars of the strategy: (1) primary prevention through human papillomavirus vaccination, (2) timely screening (by age 35 years and again by age 45 years), and (3) treatment of precancerous lesions and management of invasive cervical cancer, including palliative care.3

Elsewhere, we also reported our finding that women who died of cervical cancer in 2017 (decedents), and women who had cervical cancer in 2017 but did not die that year (nondecedents), experienced suffering that was more prevalent, complex, and severe than that caused by other malignancies and serious illnesses.2 According to our estimates, decedents had a high prevalence of moderate or severe pain (84%), vaginal discharge (66%), vaginal bleeding (61%), or loss of faith (31%). Among both decedents and nondecedents, we estimated a high prevalence of clinically significant anxiety (63% and 50%, respectively), depressed mood (52% and 38%, respectively), and sexual dysfunction (87% and 83%, respectively). Moderate or severe financial distress was found to be prevalent among decedents, nondecedents, and family caregivers (84%, 74%, and 66%, respectively). More than 40% of decedents and nondecedents were abandoned by their intimate partners. In comparison, the Lancet Commission on Palliative Care and Pain Relief reported a lower average prevalence among decedent and nondecedent patients with cancer of...
CONTEXT

Key Objective
Based on our previous study of the major types, prevalence, severity, and duration of suffering associated with cervical cancer and thus of the need for palliative care, we created an essential package of palliative care for cervical cancer (EPPCCC).

Knowledge Generated
The EPPCCC consists of a set of interventions, medicines, simple equipment, and social supports that can be applied by any clinicians with basic palliative care training. It is designed to be safe, effective for preventing and relieving all types of suffering in inpatients and outpatients with cervical cancer, useful at all levels of health care systems, and affordable even in the poorest settings.

Relevance
By assuring accessibility of the EPPCCC for all patients with cervical cancer at all levels of health care systems, governments can improve patient outcomes, provide financial risk protection for patients and families, and reduce costs to the health care system.

What Is Palliative Care for Women With Cervical Cancer?
The WHO has defined palliative care as care that improves the quality of life of patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial, and spiritual. In our view, the essence of palliative care is prevention and relief of suffering, and the problems associated with life-threatening illness also may occur with non–life-threatening conditions. For example, women with early-stage, curable cervical cancer may suffer from abandonment, depression, or treatment-related acute pain, and long-term cervical cancer survivors may suffer from chronic pain. The specific types and severity of suffering vary by illness, geopolitical situation, socioeconomic conditions, and culture.

Palliative care is a people-centered accompanying of patients and their families throughout the illness course, not only at the end of life. It should be integrated with and complement cervical cancer prevention, early diagnosis, treatment, and survivorship care, and it should be provided in all health care settings including hospitals, long-term care facilities, community health centers (CHCs), and in patients’ homes. Doctors, nurses, psychologists, social workers, and community health workers (CHWs) who provide care for patients with cervical cancer should have at least basic training in palliative care that enables them to respond effectively to the specific types of suffering in their setting. Complex or refractory suffering can be relieved by assuring accessibility of the EPPCCC for all patients with cervical cancer at all levels of health care systems, governments can improve patient outcomes, provide financial risk protection for patients and families, and reduce costs to the health care system.
most effectively by specialists in palliative care or other disciplines.

**Why Must Palliative Care Be Integrated Into Care and Treatment for Women With Cervical Cancer?**

**Medical and moral imperatives.** The human right to the highest attainable standard of health entails a human right to pain relief and palliative care for anyone with serious illness-related suffering. The human right of palliative care is especially compelling for women with cervical cancer because their suffering often is more frequent, severe, complex, or refractory than that of people with other serious illnesses. This is true not only because of the physical symptoms of cervical cancer, adverse effects of treatment, and multisystem involvement of advanced disease, but also because cervical cancer disproportionately affects the poor who often lack access to prevention, early diagnosis, and treatment, who already have late-stage disease at diagnosis in nearly 80% of cases, who often lack financial resources to access treatment when it is available, and who are at risk for stigmatization in some places.

Human rights necessarily correspond to responsibilities of governments to respect these rights. In 2014, the World Health Assembly resolved that palliative care is an ethical responsibility of health systems. It is a responsibility in governments to respect these rights. In 2014, the World Health Assembly resolved that palliative care is an ethical responsibility of health systems. It is a responsibility in part because it is feasible anywhere. Most suffering because of serious illnesses, including cervical cancer, can be relieved with inexpensive, safe, and effective medicines, equipment, therapies, and social supports provided by clinicians with basic palliative care training, including those working at community level where most patients are and wish to remain.

**Financial benefits for patients, their families, and health care systems.** Well-planned integration of basic palliative care into public health care systems can improve their performance and promote universal health coverage while also reducing costs. Data from high-income countries and upper-middle-income countries show that, when palliative care is integrated into health care systems and includes home care, it can reduce length of stay in hospitals and reduce unnecessary hospital admissions for symptom relief by enabling many patients to remain comfortable at home or in the community. Hence, palliative care can reduce hospital overcrowding and costs for overburdened health systems and provide financial risk protection for patients and their families. Within hospitals, the presence of a palliative care inpatient unit or consultation service also can improve patients’ quality of life and reduce costs, not only by reducing length of stay but also by reducing use of expensive life-sustaining treatments and cancer chemotherapy near the end of life likely to be more harmful than beneficial. Although data on cost effectiveness of palliative care in low- and lower-middle-income countries is scant, it appears that the start-up costs necessary to integrate a basic package of palliative care services into health care systems—investment in policy development, essential medicine procurement, training, and increased staffing—may yield even better returns over time by reducing costs for health care systems, reducing dysfunctional overuse of hospitals and nonbeneficial interventions, improving patients’ quality of life without shortening it, protecting patient’s families from impoverishment, and improving satisfaction of family caregivers. UHC, as defined by WHO, requires that all individuals and communities receive the full spectrum of essential, quality health services they need, from health promotion to prevention, treatment, rehabilitation, and palliative care, without suffering financial hardship. Because palliative care is an essential part of UHC, UHC is achievable only if palliative care is fully integrated into health care systems so as to be universally accessible. In low-income settings where palliative care is not widely accessible, when further treatment of serious illnesses is no longer available, affordable, or desired, patients often are sent home with no further health care coverage. In these situations in particular, UHC is achievable only through implementation of community- and home-based palliative care.

Thus, it is not only medically and morally imperative, but also financially advantageous, that at least a basic package of cost-effective palliative care be integrated with treatment of cervical cancer and universally accessible to women with cervical cancer at all levels of health care systems.

**ESSENTIAL PACKAGE OF PALLIATIVE CARE FOR CERVICAL CANCER**

The EPPCCC—for all women with cervical cancer and their family caregivers—is intended to provide health care policymakers, planners, implementers, and managers from countries of all income groups, as well as clinicians and advocates for palliative care and cervical cancer care, with the information necessary to integrate appropriate palliative care into all levels of care for women with cervical cancer and their family caregivers. Specifically, the EPPCCC is designed:

- To improve patient outcomes by preventing and relieving the most common and severe types of physical, psychological, social, and spiritual suffering associated with cervical cancer;
- To be the minimum package that should be accessible in hospitals of all levels and at CHCs;
- To be made universally accessible free of charge by public health care systems in LMICs yet also to reduce costs for health care systems by reducing hospital admissions and length of stay;
- To provide financial risk protection for patients and their families; and
- To promote UHC.

The EPPCCC consists of (Table 1):
## TABLE 1. Essential Package of Palliative Care for People Affected by Cervical Cancer

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Medicines&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Equipment</th>
<th>Social Supports&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Human Resources&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention and relief of pain or other physical suffering,&lt;sup&gt;d&lt;/sup&gt; acute or chronic</td>
<td>Amitriptyline, oral Bisacodyl (senna), oral Dexamethasone, oral and injectable Diazepam, oral and injectable Diphenhydramine (chlorpheniramine, cyclizine, or dimenhydrinate), oral and injectable Fluconazole, oral Fluoxetine (sertraline or citalopram), oral Furosemide, oral and injectable Haloperidol, oral and injectable Hyoscine butylbromide, oral and injectable Ibuprofen (naproxen, diclofenac or meloxicam), oral Lactulose (sorbitol or polyethylene glycol), oral Loperamide, oral Metaclopramide, oral and injectable Metronidazole, oral (for both oral use and vaginal insertion) Morphine, oral immediate release and injectable Naloxone, injectable Omeprazole, oral Ondansetron, oral and injectable&lt;sup&gt;e&lt;/sup&gt; Oxygen Paracetamol, oral Iron and multivitamin supplement (oral) Petroleum jelly</td>
<td>Pressure-reducing mattresses Nasogastric drainage and feeding tubes Urinary bladder catheterization kits Roller gauze for vaginal packing Elastic compression bandages Opioid lock boxes Flashlights with rechargeable batteries (if no access to electricity) Adult diapers or cotton and plastic</td>
<td>Doctors (with basic palliative care training) Nurse practitioners, midwives or feldshers (with basic palliative care training) Nurses (with basic palliative care training) CHWs (if available)</td>
<td></td>
</tr>
<tr>
<td>Prevention and relief of psychological suffering,&lt;sup&gt;f&lt;/sup&gt; acute or chronic</td>
<td>Amitriptyline, oral Dexamethasone, oral and injectable Diazepam, oral and injectable Diphenhydramine (chlorpheniramine, cyclizine, or dimenhydrinate), oral and injectable Fluoxetine (sertraline or citalopram), oral Haloperidol, oral and injectable Lactulose (sorbitol or polyethylene glycol), oral</td>
<td>Adult diapers or cotton and plastic</td>
<td>Doctors (with basic palliative care training) Nurse practitioners, midwives, or feldshers (with basic palliative care training) Nurses (with basic palliative care training) Social workers, psychologists, grief counselors, or trained and supervised lay counselors CHWs (if available)</td>
<td></td>
</tr>
<tr>
<td>Prevention and relief of social suffering, acute or chronic</td>
<td>Cash transfers or resource allocation for housing, children’s school tuition, transportation to health care facilities, or funeral costs Other resource allocation (in-kind support): food packages, blankets, sleeping mats, shoes, soap, toothbrushes, toothpaste</td>
<td></td>
<td>Social workers CHWs (if available) Peer supporters</td>
<td></td>
</tr>
<tr>
<td>Prevention and relief of spiritual suffering</td>
<td>Local spiritual counselors</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE.** Adapted from Knaul et al.<sup>4</sup> Krakauer et al.<sup>9</sup> and World Health Organization.<sup>10</sup>

Abbreviation: CHW, community health worker.

<sup>a</sup>Based on the WHO Model List of Essential Medicines 2019.<sup>11</sup> Acceptable alternative medicines are in parentheses.

<sup>b</sup>At least for patients living in extreme poverty and for one caregiver per patient.

<sup>c</sup>Doctors may be oncologists, gynecologists, surgeons, general practitioners, family doctors, clinical officers or assistant doctors, or others.

<sup>d</sup>Other physical suffering includes breathlessness, weakness, nausea, vomiting, diarrhea, constipation, incontinence, malodorous vaginal discharge, and bleeding.

<sup>e</sup>Only in hospitals that provide cancer chemotherapy or radiotherapy.

<sup>f</sup>Psychological suffering includes anxiety, depressed mood, PTSD, confusion or delirium, sexual dysfunction, and complicated grief.
• A set of four interventions;
• A set of safe, effective, inexpensive, off-patent, and widely available medicines;
• Simple and inexpensive equipment;
• Basic social supports; and
• The human resources needed to provide the medicines, equipment, and social supports effectively and safely.

Interventions

Prevention and relief of pain and other physical symptoms. In most cases, pain and other physical suffering can be adequately relieved with a set of safe, effective, and inexpensive medicines that can be prescribed responsibly by doctors, clinical officers, or assistant doctors with basic training in palliative care or by palliative care nurse specialists.

Morphine, in oral fast-acting and injectable preparations, is the most clinically important of the essential palliative care medicines and should be accessible by prescription for inpatients and outpatients with appropriate need at any hospital.44 In general, at least oral fast-acting morphine should be accessible by prescription at CHCs. All doctors who provide care for patients with cervical cancer, including primary care doctors, should complete at least basic palliative care training and, on that basis, receive legal authorization to prescribe oral and injectable morphine for inpatients and outpatients in any dose necessary to provide adequate relief as determined by the patients.10,15

Although ensuring access to morphine for anyone in need is imperative, it also is necessary to take reasonable precautions to prevent diversion and nonmedical use. Model guidelines for this purpose are available.45

Neuropathic pain is common in advanced cervical cancer and often cannot be adequately controlled with an opioid. In this situation, oral amitriptyline and oral or injectable dexamethasone can be used as adjuvants to improve analgesia if there are no absolute contraindications to their use. To reduce or eliminate malodorous vaginal discharge, the patient can be instructed to place a metronidazole powder gently to minimize risk of bleeding. In addition, two metronidazole tablets can be crushed to a fi rst-line medicine in many cases for relief of vesicovaginal or rectovaginal fistulas. In countries where plastic bags are prohibited as part of laudable environmental protection initiatives, specialized medical use should be permitted.

The necessary human resources depend primarily on the level and type of the health care delivery site and on the competency in palliative care of staff members rather than their professional designations. Any medical doctor, clinical officer, or assistant doctor with basic palliative care training should be able to prevent or relieve most pain and other physical suffering and to diagnose and treat uncomplicated anxiety disorders, depression, or delirium. In some places, nurse practitioners, midwives, or feldshers with basic palliative care training also can assume these tasks. CHWs can have a crucial role in palliative care by visiting patients and family caregivers frequently at home and reporting any problems (see section below on integration of palliative care for women with cervical cancer into primary care).

Prevention and relief of psychological suffering. Among women with cervical cancer, the high prevalence of anxiety, depressed mood, sexual dysfunction, and other psychological disorders, the suffering they cause, and the association of untreated psychological disorders with decreased treatment adherence necessitate assiduous efforts to prevent, promptly diagnose, and treat them.5,46–50 Family members of patients with cancer also may experience psychological distress because of fear of losing a loved one, caregiving burden, poverty because of loss of income and medical expenses, or prolonged grief disorder after the patient’s death.51,52

A small set of screening tools, counseling techniques, and medicines should be used not only by palliative care specialists but also by oncologists, gynecologists, and primary care doctors. Two practical screening tools for psychological and other types of distress are the Integrated Palliative Care Outcome Scale and the distress thermometer of the US National Comprehensive Cancer Network.53–55 Among the medicines in the EPPCCC are oral and injectable haloperidol and oral fluoxetine or another SSRI. Both have multiple essential uses in palliative care and are safe and easy to prescribe. For example, haloperidol is the first-line medicine in many cases for relief of nausea, vomiting, agitation, delirium, and anxiety. An SSRI, such as fluoxetine, is the first-line pharmacotherapy for depressed mood or persistent anxiety, both of which are common among women with cervical cancer and their family caregivers. Any doctor who provides primary care should be prepared and permitted to prescribe these medicines. Patients with severe or refractory psychiatric illnesses should be referred for specialist psychiatric care whenever possible.

Nonpharmacologic interventions for psychological distress include psychotherapy; supportive counseling;
psychoeducation; relaxation, art, music, and movement therapies; and guided imagery techniques. The goals of these interventions are:

- to improve coping skills and resilience,
- to reduce emotional distress,
- to reduce feelings of depression and anxiety,
- to improve body image and to help the patient to regain self esteem,
- to enhance personal growth,
- to strengthen the personal and social resources of the patient and her caregivers, and
- to improve quality of life

Not only doctors, nurses, psychologists, and social workers, but also CHWs can be trained to provide simple, culturally appropriate supportive counseling and even psychotherapy for depression. Treatment of psychological suffering may have the added benefit of improving control of the patient’s pain, fatigue, nausea, or other physical symptoms. It also can facilitate advance care planning, discussion of goals of care and treatment options, and bereavement.

Treatment of spiritual suffering may provide a funeral can become a chronic emotional burden, which can be a major financial burden for families and inability to provide a funeral can become a chronic emotional burden, locally adequate funds for a simple funeral should be made accessible for families living in extreme poverty.

**Prevention and relief of social suffering.** Social supports are especially important for women with cervical cancer in light of the finding of a high prevalence of financial difficulties, discrimination, stigmatization, social isolation, and abandonment in this population. Social support for patients and family caregivers in LMICs, where cervical cancer is prevalent in advanced cancer, yet available evidence suggests that this distress typically is not adequately addressed. Serious illness and related suffering may catalyze meaning-making but also a questioning of religious belief and of the meaning of life. Illness and suffering may be interpreted as divine punishment or a result of bad magic. Stigma associated with disease of the genitals, malodorous vaginal discharge, or concurrent HIV infection may evoke feelings of humiliation, guilt, or shame. This suffering or shame may lead to moral despair, anger with a higher power, loss of faith, or loss of the ability to find meaning in life. Family caregivers also may experience spiritual despair.

Hospitals of all levels, CHCs, and palliative care or hospice teams should establish and maintain collaborative relationships with local spiritual counselors representing the main religious or spiritual communities in the catchment area who can be called upon to provide spiritual support when requested by a patient or family. Any doctor, nurse, psychologist, or social worker, regardless of spiritual orientation, can screen for spiritual distress by asking patients with serious illnesses about sources of meaning and hope and connectedness with others. If there is concern about spiritual distress based on the screening, or if the patient requests spiritual counseling, a local spiritual care provider can be consulted. A doctor, nurse, psychologist, or social worker should speak with the potential spiritual provider in advance to explain the emotional delicacy of such situations and to minimize the risk of inadvertent exacerbation of a patient’s feelings of guilt or shame from spiritual counseling. Ideally, the spiritual provider first should conduct a more thorough spiritual assessment using an existing assessment model adapted to local culture. Based on the assessment, an appropriate plan of spiritual care can be developed. Sometimes, this may entail involvement of traditional healers. Spiritual support may help some patients or their family caregivers to make meaning of the illness, to cope better, to feel less afraid or ashamed, or to feel more at peace.

**Integrating Palliative Care Into Standard Practice of Gynecologic Oncology**

**Locations of care.** The EPPCCC should be accessible wherever women with cervical cancer seek or receive care as shown in Table 2. In LMICs, where cervical cancer typically is diagnosed at an advanced stage at a hospital or regional general hospital or cancer center (second- or third-level hospital), all such hospitals should have a palliative care department or team with capacity to assess all newly diagnosed inpatients and outpatients for physical, psychological, social, or spiritual suffering. These teams also should be able to initiate palliative care, to integrate it with disease-modifying treatments early as part of the overall treatment plan, to create a plan for continued palliative care at lower levels or at home for outpatients and for inpatients before discharge, and to control refractory symptoms that cannot be controlled at lower levels.
must be made, palliative care team members should be prepared to assist.

All district (first-level) hospitals should have at least one or two doctors and nurses with at least basic palliative care training who are assigned to provide basic palliative care with the EPPCCC as one of their responsibilities. WHO has published a model training curriculum in basic palliative care for doctors, clinical officers, or assistant doctors lasting 30-40 hours.10,86 With this training, they will be capable of addressing the needs of inpatients and outpatients with uncomplicated palliative care needs. These needs include adjustment in doses of opioid analgesics or other medicines to control symptoms that are uncomplicated but changing because of disease progression or treatment side effects. For dying patients whose symptoms are adequately controlled but whose families are unable to care for them at home, these teams also can provide inpatient end-of-life (hospice) care if the CHCs nearest the patient's home are unable to do so. Palliative care teams at district level also have a crucial role in supervising and providing backup for palliative care providers at community level.

At least two clinicians at every CHC—ideally at least one doctor and one other clinician—also should have at least basic palliative care training, and as soon as possible, all primary care clinicians should have this training. Per WHO, basic palliative care training lasting at least 30 hours should enable trainees to provide basic outpatient symptom control and supervise CHWs who visit patients at home.10 Standard operating procedures should be in place to assure easy communication and smooth transfer of patients between levels of the health care system.10

Basic and more advanced courses in palliative care are offered in some LMICs in all regions by hospitals, universities, or nongovernmental organizations. A directory of palliative care training programs is maintained by the International Association for Hospice and Palliative care.87 However, the need for all levels of palliative care training in LMICs remains high, and specialist training program are available only in a few countries. Likewise, even basic palliative care services and many essential palliative medicines, including morphine, remain unavailable to most inpatients and outpatients in LMICs.6

Assessment for physical, psychological, social, or spiritual suffering is indicated at the time of diagnosis of cervical cancer of any stage, and palliative care should be initiated based on the assessment.10 In LMICs, pain, vaginal discharge, vaginal bleeding, anxiety, depression, sexual dysfunction, or social distress often are present at the time of diagnosis and require palliation, regardless of the treatment plan and whether or not cure is possible.3 As the treatment plan is formulated, palliative care also entails helping patients and possibly their families, as appropriate, to understand the illness and treatment plan, helping to assure that the patient has the resources to adhere to the treatment, providing emotional support, and sometimes helping to reach an agreement between the patient, family, and treatment team on the optimum goal(s) of care in light of the clinical situation and the patient's values.

During treatment with radiotherapy, chemotherapy, or surgery, palliative care entails continued relief of any disease-related symptoms but also prevention and relief of any adverse effects of treatment, some of which may persist for months or years after treatment is completed. It also entails continued psychological, social, and spiritual support as needed to maximize the patient's ability to cope with the illness and adhere to treatment.

All gynecologists who care for patients with cervical cancer and all oncologists should have intermediate-level palliative care training (defined by WHO as 60-80 hours) and be capable of integrating palliative care with disease treatment along with nurses and psychologists or social workers.10 Provision of effective palliative care does not always require much time from busy oncologists or gynecologists but rather a recognition of its importance and adequate training. Plans should be made for palliative care teams at major cancer centers in LMICs to be led as soon as possible by palliative care specialists skilled at relieving even complex and refractory symptoms. Elsewhere, we describe an augmented package of palliative care that should be made available whenever feasible at major cancer centers for specialists in palliative medicine and other disciplines to treat the most severe or refractory suffering.89 Palliative care specialists also should participate in person or virtually in tumor board discussions. However, most palliative care can and should be provided by other medical specialists and by primary care clinicians.

Integration of palliative care for women with cervical cancer into primary care. All 194 WHO member states have agreed that palliative care is an essential function of primary care and should be integrated with disease prevention and treatment and rehabilitative services.10,15,88,89 Thus, all primary care doctors and other primary care clinicians, including family medicine specialists, should be required to undergo at least basic palliative care training (30-40 hours). With this training, and with the EPPCCC, primary care clinicians at district (first-level) hospitals and CHCs will be able to provide integrated, people-centered health services for women suffering from or at risk for cervical cancer including human papillomavirus vaccination, cervical cancer screening, relief of uncomplicated disease-related symptoms and adverse effects of treatment, psychosocial and adherence support, and basic end-of-life care.89-92 Standard operating procedures should be in place to enable primary care clinicians to consult colleagues at higher levels about difficult cases and to transfer patients when necessary.10 Doctors and other clinicians at CHCs also can supervise CHWs or volunteers who visit patients in need of palliative care at home.10 With as little as 3 to 6 hours of training, CHWs or volunteers not only can provide important
### TABLE 2. Locations and Types of Palliative Care for Women With Cervical Cancer and Other Gynecologic Cancers

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Second- and Third-Level (Provincial, Regional, and Specialty) Hospitals</th>
<th>First-Level (District) Hospitals</th>
<th>CHCs</th>
<th>Home Care or Mobile Outreach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial control of moderate or severe physical or psychological symptoms</td>
<td>Palliative care team consisting of full- or part-time doctors with at least intermediate-level training in palliative care, nurses, psychologist, and/or social worker</td>
<td>Small palliative care team consisting of one or two part-time doctors with basic or intermediate-level training in palliative care, nurse(s), and ideally also a social worker</td>
<td>Inpatient palliative care</td>
<td>Inpatient palliative care</td>
</tr>
<tr>
<td>Control of refractory suffering</td>
<td>Ideally, a palliative care specialist physician should lead the team at major cancer centers and referral hospitals</td>
<td>Ideally also inpatient hospice care if the family is unable to provide adequate care at home and if no inpatient care is available at CHCs</td>
<td>Outpatient palliative care ward</td>
<td>Outpatient palliative care clinic</td>
</tr>
<tr>
<td>Help with decisions about goals of care</td>
<td>Inpatient palliative care ward</td>
<td>Consultation by phone for clinicians at lower level, as needed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Planning for care at home or at lower level</td>
<td>Outpatient palliative care clinic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social supports</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Ongoing care for patients with well-controlled symptoms | Small palliative care team consisting of one or two part-time doctors with basic or intermediate-level training in palliative care, nurse(s), and ideally also a social worker | Nurse(s) or midwives and possibly also a doctor, social worker, or lay counselor with basic training in palliative care to provide outpatient care and home visits as needed | CHWs provide surveillance and emotional support as often as daily |
| Social supports | Inpatient hospice care if the family is unable to provide adequate care at home and if no inpatient care is available at CHCs | Ideally also inpatient hospice care if the family is unable to provide adequate care at home | Visits as needed by a nurse, doctor, social worker, or trained lay counselor from the CHC with basic training in palliative care |

| Social supports | Small palliative care team consisting of one or two part-time doctors with basic or intermediate-level training in palliative care, nurse(s), and ideally also a social worker | Nurse(s) or midwives and possibly also a doctor, social worker, or lay counselor with basic training in palliative care to provide outpatient care and home visits as needed | CHWs provide surveillance and emotional support as often as daily |

**NOTE.** Adapted from Krakauer et al.9 and World Health Organization.10

Abbreviations: CHC, community health center; CHW, community health worker.

emotional support, but also recognize uncontrolled symptoms and improper use of medicines, identify unfulfilled basic needs for food, shelter, or clothing, and generally serve as the eyes and ears of their clinician-supervisors at a CHC by alerting them via mobile phone to such problems.8,10 Where there are no CHWs, provision should be made for clinicians from CHCs to visit patients at home. Health care systems also should plan to enable busy clinicians from CHCs to make home visits when a visit may enable a patient to remain comfortable at home rather than go to the hospital.

**End-of-life care.** When any further disease-modifying treatment is deemed unlikely to provide benefit in the context of the patient’s values, or likely would be more harmful than beneficial, a conversation about goals of care with the patient and/or family is necessary. The prognostic understanding of the patient or family should be explored gently and corrected as needed and as culturally appropriate, and it should be explained that care to maximize comfort and quality of life may be the best that medicine can offer under the circumstances. Whether this situation occurs in the hospital or in the community, good end-of-life care should include:

- Aggressive relief of pain and any other physical or psychological symptoms;
- Anticipation of symptoms that might worsen or develop in the future, and preparation of a plan to protect the patient from resultant suffering;
- Decisions about location of care and under what circumstances, if any, transfer to higher or lower level should be considered;
- Psychological, social, or spiritual support as needed.

If there is agreement on comfort as the sole goal of care for a patient in the hospital, and if one or more symptoms are not well controlled, the patient should remain in the hospital or in an inpatient hospice or palliative care facility at least until a regimen is found to maintain comfort. For patients likely to die within a few days or on the way home, discharge should be considered only if the patient insists after understanding...
Women with advanced cervical cancer are at risk for various sudden and/or severe symptoms including pain crisis, bowel obstruction, and massive vaginal hemorrhage with exsanguination. When planning the location of end-of-life care, the risk of these or other severe complications should be considered carefully with the patient and/or family. Elsewhere, we describe interventions to prevent or control massive hemorrhage as part of an augmented package of palliative care for women with cervical cancer that should be made available as soon as feasible in major cancer centers.

However, where such interventions are not available or desired, or if the patient insists on going home despite uncontrolled symptoms or high risk of sudden or severe suffering, every effort still should be made to inform and equip community-based primary care clinicians to provide the best possible palliation. In particular, if there is a significant risk of massive hemorrhage, community providers and family members should be instructed to have many dark towels available to catch the blood and given the following guidance on how to respond when bleeding occurs:

- A primary care provider should go to the patient’s home and reassure the patient and family members that the situation will be managed.
- Any CHW or volunteer who knows the family should go to the home to offer accompaniment to the patient and family through the event.
- The dark towels should be used to catch the blood and replaced when soaked.
- An intravenous (IV) or subcutaneous catheter should be placed promptly, and any pain or anxiety of the patient should be treated aggressively with IV or subcutaneous opioid and benzodiazepine.
- Any dyspnea or chest pain that occurs as the patient exsanguinates should be relieved aggressively with IV opioid.
- Vaginal packing with roller gauze may be considered but often exacerbates discomfort.

In conclusion, based on available data of palliative care needs among women with cervical cancer, we created an EPPCCC that consists of safe, effective, readily available, and inexpensive medicines, simple equipment, and social supports that can and should be administered as part of standard gynecologic, oncologic, and primary care by clinicians with at least basic training in palliative care. Integration of the EPPCCC into care for women with cervical cancer should be part of the overall integration of palliative care into health care systems as urged by WHO that is indispensable to achievement of UHC. However, women with cervical cancer appear to bear an unusually high burden of suffering that calls for a vigorous response from public health officials, gynecologists, oncologists, and primary care providers.

AFFILIATIONS

1Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA
2Departments of Medicine and of Global Health & Social Medicine, Harvard Medical School, Boston, MA
3Department of Palliative Care, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam
4Department of Medicine, Harvard Medical School, Boston, MA
5Harvard School of Public Health, Boston, MA
6Department of Anaesthesiology, Aga Khan University Medical College, Karachi, Pakistan
7Department of Obstetrics and Gynecology, University of Botswana, Gaborone, Botswana
8Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT
9Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA
10Université Épiscopale d’Haiti, Port-au-Prince, Haiti
11Faculté des Sciences Infirmières de Leogane, Leogane, Haiti
12Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA
13Worldwide Hospice Palliative Care Alliance, Fairfax, VA
14Gynecologic Oncology Unit and Palliative Care Service, Clínica Las Condes, Santiago, Chile
15Normah Medical Specialist Center, Sarawak, Malaysia
16Cancer Institute of Cheikh Anta Diop University, Dakar, Senegal
17Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC
18Radiation and Isotope Centre, Oncology Hospital, Khartoum, Sudan
19Comboni College of Science and Technology, Khartoum, Sudan
20Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, MA
21Department of Obstetrics and Gynecology, Harvard Medical School, Boston, MA
22Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
23Botswana-UPenn Partnership, Gaborone, Botswana
24Department of Gynecology and Obstetrics, Johannes Gutenberg University Medical Center, Mainz, Germany
3Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA
2Department of Palliative Care and Geriatrics, Department of Anesthesiology and Pain Medicine, Massachusetts General Hospital, Boston, MA
1Institute of Palliative Medicine, Medical College, Kerala, India
College of Public Health Science, Chulalongkorn University, Bangkok, Thailand
School of Social Work, Boston College, Boston, MA
3University Medical Center, Ho Chi Minh City, Vietnam
Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Hope Institute Hospital, Kingston, Jamaica
University of the West Indies, Kingston, Jamaica
3National Cancer Institute, Bethesda, MD
Department of Non-communicable Diseases, World Health Organization, Geneva, Switzerland

CORRESPONDING AUTHOR
Eric L. Krakauer, MD, PhD, Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital, 55 Fruit St, Founders 600, Boston, MA 02114; e-mail: ekrakauer@hms.harvard.edu.

DISCLAIMER
E.F., C.V., and E.L.K. are staff members or consultants of the WHO. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the WHO.

SUPPORT
Funding was provided by the WHO and Unitaid.

AUTHOR CONTRIBUTIONS
Conception and design: Eric L. Krakauer, Xiaoxiao Kwete, Gauhar Afshan, Lawrence F. Borges, Raimundo Correa, Nahla Gafer, Annekathryn Goodman, Cherian Varghese, Elena Fidarova
Administrative support: Khadijatou Kane, Elena Fidarova
Provision of study materials or patients: Khadijatou Kane, Raimundo Correa, Mamadou Diop, Nahla Gafer, Maryam Rassouli
Collection and assembly of data: Eric L. Krakauer, Khadijatou Kane, Xiaoxiao Kwete, Nahla Gafer, Annette Hasenburg, Mihir Kamdar, Suresh Kumar, Maryam Rassouli, Elena Fidarova
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

REFERENCES

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Eric L. Krakauer
Employment: (I) My wife is employed by Inform Diagnostics and Foundation Medicine

Xiaoxiao Kwete
Employment: Yaozhi Co Ltd
Stock and Other Ownership Interests: Expat Inc
Research Funding: Roche

Travel, Accommodations, Expenses: Expat Inc

Shekinah N. Elmore
Stock and Other Ownership Interests: Teladoc
Consulting or Advisory Role: Best Doctors Inc, Wild Type

Annette Hasenburg
Honoraria: AstraZeneca, Med Update, Pfizer, Roche, Streamedup!, Tesaro, MedConcept, LEO Pharma
Consulting or Advisory Role: PharmaMar, Tesaro, Roche, AstraZeneca, LEO Pharma, GlaxoSmithKline/MSD
Travel, Accommodations, Expenses: AstraZeneca, MedConcept, Roche, Streamedup!, Tesaro, MedUpdate, Pfizer

Mihir Kamdar
Leadership: Amorsa Therapeutics
Stock and Other Ownership Interests: Amorsa Therapeutics
Consulting or Advisory Role: Medtronic, Fern Health

Cristiana Sessa
Consulting or Advisory Role: Basilea

Ted Trimble
Consulting or Advisory Role: Merck, GlaxoSmithKline, Inovio Pharmaceuticals
Research Funding: Frantz Viral Therapeutics

No other potential conflicts of interest were reported.

ACKNOWLEDGMENT
We are grateful to the following for helpful comments on drafts of the paper: Sally Agallo Kwenda, Esther Cege-Munyoro, Liliana de Lima, Lailatul Ferdous, Rei Haruyama, Kim Hulscher, Elizabeth Matthfeld, Diana Nevzorova, MR Rajagopal, Julie Torode, and Linda Van Le.


29. Rabow MW: What are the arguments that show outpatient palliative care is beneficial to medical systems? In Goldstein NE, Morrison RS (eds): Evidenced-Based Practice of Palliative Care. Amsterdam, the Netherlands, Elsevier, 2012


70. NCC.00000000000000812; 2014; 17:1229-1249, 2019
75. Krakauer et al